SPAC Daily: Tues, November 15

by | Nov 15, 2022

Chart of the Day – FOXO in Turmoil

Today in SPACs

  • Frazier Lifesciences Acquisition (FLAC) shareholders approved its NewAmsterdam Pharma and will trade as NAMS next week. Just 32% of shares redeemed (which is a multi-month low), though some of that can be attributed to a non-redemption agreement
  • G&P Acquisition Corp. (GAPA) will liquidate its shares and dissolve on November 30
  • Liberty Media Acquisition Corporation (LMACA) approved its early dissolution and will wind up on 12/1, 44.5M shares elected to redeem immediately for $10.07
  • OceanTech Acquisitions I Corp. (OTEC) will take OTC traded Majic Wheels (MJWL) in a SPAC transaction

SPAC Calendar

Recent Analysis


The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.